Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.32 |
| ▸ | SPHK2 | Q9NRA0 | 5/20 | 0.31 |
| ▸ | SPHK1 | Q9NYA1 | 5/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20144886 | 1.00 | POLB (0.47) | POLBL3MBTL1LMNAMEN1KMT2A | |
| SCHEMBL20144697 | 0.95 | L3MBTL1 (0.47) | POLBL3MBTL1LMNAMEN1KMT2A | |
| SCHEMBL20144698 | 0.95 | L3MBTL1 (0.47) | POLBL3MBTL1LMNAMEN1KMT2A | |
| SCHEMBL20095597 | 0.93 | POLB (0.45) | POLBL3MBTL1LMNAMEN1KMT2A | |
| SCHEMBL22220339 | 0.93 | POLB (0.48) | POLBL3MBTL1LMNAMEN1KMT2A | |
| SCHEMBL19172490 | 0.93 | POLB (0.48) | POLBL3MBTL1LMNAMEN1KMT2A | |
| SCHEMBL31282369 | 0.91 | POLB (0.42) | POLBL3MBTL1LMNAMEN1KMT2A | |
| SCHEMBL30706645 | 0.91 | POLB (0.42) | POLBL3MBTL1LMNAMEN1KMT2A | |
| SCHEMBL2266863 | 0.91 | POLB (0.42) | POLBL3MBTL1LMNAMEN1KMT2A | |
| SCHEMBL20144884 | 0.91 | L3MBTL1 (0.42) | POLBL3MBTL1LMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11548888-B2 | KRas G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2023-01-10 | — | — | US | disclosed |
| US-11548888-B2 | KRas G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2023-01-10 | — | — | US | disclosed |
| US-20200331911-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2020-10-22 | — | — | US | disclosed |
| US-20200331911-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2020-10-22 | — | — | US | disclosed |
| WO-2020146613-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2020-07-16 | — | — | WO | disclosed |
| US-20120108748-A1 | SOLID PHASE PEPTIDE SYNTHESIS OF PEPTIDE ALCOHOLS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2012-05-03 | — | — | US | disclosed |
| WO-2011000848-A1 | SOLID PHASE PEPTIDE SYNTHESIS OF PEPTIDE ALCOHOLS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2011-01-06 | — | — | WO | disclosed |
| EP-2270025-A1 | Solid phase peptide synthesis of peptide alcohols | Centre National pour la Recherche Scientifique (CNRS) (FR) | 2011-01-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108748-A1 | SOLID PHASE PEPTIDE SYNTHESIS OF PEPTIDE ALCOHOLS | VIP, ERG28, PSAP | POLB 866/4885L3MBTL1 970/4885LMNA 3745/4885 |
| US-11548888-B2 | KRas G12C inhibitors | KRAS, NRAS, HRAS | POLB 1699/4885L3MBTL1 2112/4885LMNA 2991/4885 |
| US-20200331911-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | POLB 1699/4885L3MBTL1 2112/4885LMNA 2991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.